Arvinas, Inc.
ARVNNext catalyst
ARV-806
KRAS G12D Mutation
Get an email about ARVN's next catalysts
Track Arvinas (ARVN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 3 more upcoming events in our data (earnings, Phase 3 readout, Phase 2 readout).See the timeline
4 upcoming, 0 past
ARVN Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.80 | FQ end Sep/2026 | Call: tbd
ARV-806 Phase 2 Est. Readout
Primary completion for ARV-806 trial (NCT07023731) in KRAS G12D Mutation
SourceVepdegestrant (ARV-471/PF-07850327) Phase 3 Est. Readout (VERITAC-3)
Estimated primary completion for Vepdegestrant (ARV-471/PF-07850327) trial (NCT05909397) in Breast Cancer. Topline data typically follows completion by weeks to months.
SourceARV-471 Phase 2 Est. Readout
Estimated primary completion for ARV-471 trial (NCT05548127) in Breast Cancer. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Vepdegestrant (ARV-471/PF-07850327)
Breast Cancer
ARV-110
Prostate Cancer Metastatic
ARV-806
KRAS G12D Mutation
ARV-471
Breast Cancer
Vepdegestrant
Breast Cancer
PF-07220060
Breast Cancer
ARV-6723
Advanced Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Vepdegestrant (ARV-471/PF-07850327) | Phase 3 | Breast Cancer | - | - |
ARV-110 | Phase 2 | Prostate Cancer Metastatic | - | - |
ARV-806 | Phase 2 | KRAS G12D Mutation | - | - |
ARV-471 | Phase 2 | Breast Cancer | - | - |
Vepdegestrant | Phase 2 | Breast Cancer | - | - |
PF-07220060 | Phase 2 | Breast Cancer | - | - |
ARV-6723 | Phase 2 | Advanced Solid Tumor | - | - |
Breast Cancer
1 drug in this indication
KRAS G12D Mutation
1 drug in this indication
Prostate Cancer Metastatic
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Arvinas, Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Arvinas, Inc.'s (ARVN) pipeline across Phase 3, Phase 2. Its lead program is Vepdegestrant (ARV-471/PF-07850327) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Arvinas, Inc.'s next FDA catalyst?→
Arvinas, Inc.'s (ARVN) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ARVN biotech catalysts?→
Add ARVN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Arvinas, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.